New radioactive tracer aims to spot colorectal cancer more clearly
NCT ID NCT07597759
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a radioactive tracer called 68Ga-NODAGA-SNA009 in 12 people with colorectal cancer. The tracer targets a protein (GPA33) found on cancer cells and is used with PET scans to see where the cancer is in the body. The main goals were to check safety and measure how the tracer spreads and how much radiation it delivers. This study does not test treatment, only imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-NODAGA-SNA009 (a radioactive tracer for PET imaging)
What this could lead to
If successful, this could lead to a more precise way to detect colorectal cancer using PET scans, helping doctors see tumors better.
What could go wrong
This is a very early, small study (12 people) focused on safety and imaging, not treatment. The tracer may not work well in larger groups or improve patient outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China